Insights
Search Results
Client Highlights
6.02.26
Firm Advises 137 Ventures and BANNER VC on Impulse Space’s $500 Million Series D Financing
On June 2, 2026, Impulse Space, an in-space mobility leader, announced it has raised $500 million in Series D funding, bringing the company’s total capital raised to over $1 billion. The funding will support the company’s hiring and manufacturing growth plans in its efforts to build in-space mobility infrastructure. The funding round was co-led by 137 Ventures and BANNER VC with participation from Founder’s Fund, Lux Capital, and Linse Capital. Wilson Sonsini Goodrich & Rosati advised 137 Ventures and BANNER VC on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Advises Lattice Semiconductor on $1.65 Billion Acquisition of AMI
On May 4, 2026, Lattice Semiconductor announced it has entered into a definitive agreement with THL Partners to acquire AMI, a leader in platform firmware and infrastructure manageability for cloud and AI. The planned acquisition advances Lattice Semiconductor’s strategy to expand its position in server, AI, and cloud applications spanning hardware, security, manageability, and control. Wilson Sonsini Goodrich & Rosati is advising Lattice Semiconductor on the transaction.
Client Highlights
4.17.26
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises OnKure Therapeutics on $150 Million Private Placement
On March 27, 2026, OnKure Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel precision medicines, announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million. Wilson Sonsini Goodrich & Rosati advised OnKure on the transaction.
Client Highlights
12.17.25
Wilson Sonsini Advises Hexagon Bio on Multimillion-Dollar Joint Venture with Corteva
On December 16, 2025, Corteva, a global leader in agricultural technology, and Hexagon Bio, a biotechnology company pioneering a new way to discover nature-derived medicine, announced a multimillion-dollar joint venture (JV) to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva. Wilson Sonsini Goodrich & Rosati advised Hexagon Bio on the transaction.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
Client Highlights
12.15.25
Wilson Sonsini Advises Excellergy on $70 Million Series A
On October 13, 2025, Excellergy, a biotechnology company developing a new class of allergy therapeutics, announced its launch with a $70 million Series A financing to advance its pipeline of first-in-class allergic Effector Cell Response Inhibitors (ECRIs). Excellergy is backed by leading healthcare investors, with Samsara BioCapital serving as the Series A lead with co-investments from Red Tree Venture Capital and Decheng Capital. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
9.24.25
Wilson Sonsini Advises Manas AI on $26 Million Seed Extension
On September 23, 2025, Manas AI, a full-stack, AI native drug discovery and development company, announced the closing of a $26 million Seed Extension and the addition of its new Co-Founder and Chief Technology Officer, Ujjwal Singh. Wilson Sonsini advised Manas AI on the transaction.
Client Highlights
8.08.25
Wilson Sonsini Advises Docyt on $12 Million Pre-Series B
On August 6, 2025, Docyt, an AI-powered accounting automation platform, announced the launched of its new AI engine, High Precision Accounting Intelligence (HpAI), purpose-built to automate complex accounting workflows with unmatched precision. The product release follows Docyt’s recent pre-Series B funding round, which added $12 million in new capital led by Pivot Investment Partners and existing investors. Wilson Sonsini Goodrich & Rosati advised Docyt on the transaction.
Client Highlights
4.08.25
Wilson Sonsini Advises Neurona Therapeutics on $102 Million Oversubscribed Financing
On April 3, 2025, Neurona Therapeutics, a clinical-stage, privately held biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, announced the completion of an upsized and oversubscribed $102 million financing. Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, and Spur Capital Partners all participated in the financing round. Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction.
Client Highlights
2.26.25
Firm Advises Investors on Eikon Therapeutics’ $350.7 Million Series D
On February 26, 2025, Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, announced the initial closing of a $350.7 million Series D financing. The round was led by Eikon’s existing investors, with participation from new investors. Wilson Sonsini Goodrich & Rosati represented certain of the investors in the transaction.
The investment syndicate is composed of top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms, including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others.
Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma. In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers.
The Wilson Sonsini team that advised the investors on the transaction included Ken Clark, Christina Poulsen, Jacie Valentine, and Jake Morales.
For more information, please see Eikon’s news release.
The investment syndicate is composed of top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms, including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others.
Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma. In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers.
The Wilson Sonsini team that advised the investors on the transaction included Ken Clark, Christina Poulsen, Jacie Valentine, and Jake Morales.
For more information, please see Eikon’s news release.
Client Highlights
1.29.25
Wilson Sonsini Advises Manas AI on $24.6 Million Fundraise
On January 27, 2025, an exclusive article by The Wall Street Journal announced that Manas AI, an artificial intelligence drug discovery start-up founded by Siddhartha Mukherjee, a Columbia professor and author of The Emperor of All Maladies, has launched with $24.6 million in initial funding. Manas AI will first focus on breast cancer, prostate cancer, and lymphoma before broadening its scope to include other illnesses. Tech investor and LinkedIn co-founder Reid Hoffman led the funding round with VC firm General Catalyst. Greylock also participated.